NCT01917708View on ClinicalTrials.gov

Bone Marrow Transplant With Abatacept for Non-Malignant Diseases

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 19, 2019

Study Completion Date

September 19, 2019

Conditions
Hurler SyndromeFanconi AnemiaGlanzmann ThrombastheniaWiskott-Aldrich SyndromeChronic Granulomatous DiseaseSevere Congenital NeutropeniaLeukocyte Adhesion DeficiencyShwachman-Diamond SyndromeDiamond-Blackfan AnemiaDyskeratosis-congenitaChediak-Higashi SyndromeSevere Aplastic AnemiaThalassemia MajorHemophagocytic LymphohistiocytosisSickle Cell Disease
Interventions
DRUG

Abatacept

All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.

Trial Locations (1)

30322

Children's Healthcare of Atlanta, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT01917708 - Bone Marrow Transplant With Abatacept for Non-Malignant Diseases | Biotech Hunter | Biotech Hunter